I am 58 y.o. and have recurrent PCa; 93 mos. post-RP my PSA is now 6 and I am probably about to start ADT. My uro suggests “Lupron” monotherapy until PSA goes undetectable and then off until some target level, and so on. Is this the current protocol of choice? Thank you, Dr. Myers. Bill Denton/Memphis

I think you missed several major opportunities to better control your disease. First, when you PSA started to increase, you had the chance to use radiation to put you back in remission. Second, there is now a wide range of options to slow the PSA doubling time and delay the need for hormonal therapy.

Now, with a PSA of 6 ng/ml and what appears to be a slow PSA doubling time, the first question you should be asking is where the cancer might be located. Much to my surprise, recent research strongly suggests your cancer may still be contained within the pelvis. It is likely to be in the prostate bed left after surgery or in the lymph nodes in the pelvis. This is especially true given the slow PSA doubling time you have had.

The first thing you should do is at least get a bone scan and CT scan to see if you can localize the cancer. A Prostascint scan is a better tool to find cancer in the pelvic lymph nodes, but it is far from perfect. If these tools find the cancer, the radiation therapist has a clear target to focus on.

If you do use hormonal therapy, it is important to recognize that your cancer has been slowly growing and treatment should recognize this fact. Because your cancer has been so nonaggressive, Lupron alone is very likely to put you into a complete remission. In fact, Casodex and Proscar/Avodart in combination would also likely to do that. In this process, the amount of cancer will be markedly reduced. This will likely be complete within 9-12 months. At that time, hormonal therapy can stop.

When you stop hormonal therapy, I think it is critical for you to consider trying to slow or stop your PSA progression. There are many options for this. If you do this, you are likely not to need to go back on hormonal therapy for many years.

Finally, the most aggressive approach to your disease would be to combine hormonal therapy with radiation to the prostate bed and pelvic lymph nodes.

Ask Dr. Espinosa

Geo Espinosa, N.D., L.Ac, CNS, RH (AHG) is the Director of the Integrative Urological Center at New York University Langone Medical Center. Before joining NYU, Dr. Espinosa was a clinician, researcher and director of clinical trials at the Center for Holistic Urology at Columbia University Medical Center. He is a licensed naturopathic doctor, licensed acupuncturist, a Certified Nutrition Specialist and a Registered Herbalist. Dr. Espinosa is an author of the naturopathic entry in 1000 Cures for 200 ailments, by Harper Collins; March 2007 and “Prostate cancer – Nutrients that may slow its progression,” Food and Nutrients in Disease Management - Maryland: Cadmus Publishing, 2009.

Ask Dr. Myers

Medical oncologist and prostate cancer survivor, Dr Charles "Snuffy" Myers was a key player in creating AZT, Suranim, and Phenylacetate while working at the National Institute of Health. With over 250 research papers published, Myers is one of the leading developers of today's prostate cancer canon on both the research and treatment side of the test tube. Former Cancer Director at the University of Virginia, Myers opened the American Institute for Diseases of the Prostate in 2002 to provide men with the kind of comprehensive care that saved his own life. Dr. Myers has long been popular among prostate cancer patients as a speaker because of his ability to explain science and medicine in easy-to-understand language.

Ask Dr. Latini

Dr. Latini welcomes your questions about the psycho-social dimensions of Prostate Cancer, particularly those presented by Gay and Bisexual men. Dr. Latini is an assistant professor of urology at Baylor College of Medicine. Before joining Baylor, he spent six years in the Department of Urology at the University of California, San Francisco. Dr. Latini is a clinical health psychologist whose work concentrates on cancer survivorship and symptom management for persons living with genitourinary cancer.